Discovery of potent α1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives

Suzuki, Shinya; Okano, Toshio; Horiuchi, Rie; Hareyama, Nana; Amikura, Kazutoshi; Yamamoto, Naoyoshi; Yoshizawa, Yoshitaka; Yagi, Mai; Serizawa, Kanako; Hayashi, Ryoji

doi:10.1016/j.bmcl.2015.05.049

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strategy of using a cell line that expresses α 1L ‐adrenoceptors is appealing as it would be very useful for drug discovery in the field of treatment for LUTS associated with BPH, and CHO cells transfected with CRELD1α have been used to discover ligands that are selective for α 1L ‐adrenoceptors (Suzuki et al, ). Nevertheless, the defining experiments that confirm that CRELD1α is the protein that interacts with the α 1A ‐adrenoceptor to convert its pharmacology to that of an α 1L ‐adrenoceptor are still to be conducted.…”

Section: Possible Candidates: Cysteine‐rich With Egf‐like Domainmentioning

confidence: 99%

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?

White

Silva

Lim

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

The α1A‐adrenoceptor is abundantly expressed in the lower urinary tract and is the principal therapeutic target for the symptomatic treatment of lower urinary tract symptoms in men. Prazosin has a lower affinity for the lower urinary tract α1A‐adrenoceptor than α1A‐adrenoceptors found in other parts of the body. This has led to the lower urinary tract α1A‐adrenoceptor being subclassified as an α1L‐adrenoceptor. It was demonstrated that this pharmacologically distinct α1L‐adrenoceptor is a product of the α1A‐adrenoceptor gene, but the mechanism by which this altered phenotype is achieved remains a mystery. Hypotheses for this altered pharmacology include the presence of an interacting protein such as cysteine‐rich with EGF‐like domain (CRELD) 1 or other GPCRs such as the CXCR2 chemokine or 5‐HT1B receptor. Alternatively, the influence of breast cancer resistance protein (BCRP) efflux transporters on the pharmacology of α1A‐adrenoceptors has also been investigated. These and other hypotheses will be described and discussed in this review. Linked Articles This article is part of a themed section on Adrenoceptors—New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc

show abstract

Section: Possible Candidates: Cysteine‐rich With Egf‐like Domainmentioning

confidence: 99%

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?

White

Silva

Lim

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Ene reactions of 2-borylated α-methylstyrenes: a practical route to 4-methylenechromanes and derivatives

et al. 2019

View full text Add to dashboard Cite

show abstract

Discovery of potent α1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives

Cited by 2 publications

References 10 publications

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?

Ene reactions of 2-borylated α-methylstyrenes: a practical route to 4-methylenechromanes and derivatives

Contact Info

Product

Resources

About

Discovery of potent α1L-adrenoceptor agonists: Design and synthesis of bicyclic derivatives

Cited by 2 publications

References 10 publications

What makes the α1A‐adrenoceptor gene product assume an α1L‐adrenoceptor phenotype?

What makes the α1A‐adrenoceptor gene product assume an α1L‐adrenoceptor phenotype?

Ene reactions of 2-borylated α-methylstyrenes: a practical route to 4-methylenechromanes and derivatives

Contact Info

Product

Resources

About

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?

What makes the α_1A‐adrenoceptor gene product assume an α_1L‐adrenoceptor phenotype?